CHF Solutions Expands Commercial Presence in Europe with Distribution Arrangement for Germany, Austria and Switzerland
Approximately 2.0 million individuals suffer from heart failure in these three countries, including 1.4 million individuals in
“We continue to execute on our goal to expand worldwide access to aquapheresis therapy,” said
“We are pleased to be partnering with
About Aquadex FlexFlow and Aquadex SmartFlow Systems
The Aquadex FlexFlow and Aquadex SmartFlow systems are clinically proven therapies that provide a safe, effective, and predictable method of removing excess fluid from patients suffering from fluid overload. The Aquadex FlexFlow system is indicated for temporary (up to eight hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy, and for extended (longer than 8 hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization. The company has submitted an application to the
Certain statements in this release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements about the company’s growth internationally. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our ability to execute on our commercial strategy, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the
Chief Financial Officer
1. Cardiac Failure Review 2017; 3(1):7-11.
2. Swiss Med Wkly. 2011;141:w13171.
4. Testani, et.al. “Early Rapidly and Highly Accurate Prediction of Poor Loop Diurectic
Natriuretic Response in Patients with Heart Failure.” Circ Heart Fail. 2016; 9:e002370.
Source: CHF Solutions, Inc.